- Registration projects in health and health care
Registration projects in health and health care
The reimbursement conditions for 6 specific types of antiviral hepatitis C medication for the treatment of chronic hepatitis C patients will be extended and 2 new ones will be added. This extended reimbursement will be active starting from 1.1.2017 and is agreed upon for a period of 2 years between RIZIV-INAMI and the 5 involved pharmaceutical companies via a contract of type Art.81 signed with the RIZIV-INAMI..
The hepatitis C antiviral medication is on the list of Chapter 4 medication, which requires the treating physician to fill out a...
Mandated data collection on cystic fibrosis patients that are prescribed Kalydeco® in Belgium, after reimbursement approval dd 01FEB2016 as per agreement with RIZIV/INAMI dd 26NOV2015 (Kb. art 81 #7930000).
For a number of diseases/disorders, personalized treatment today offers a great added value compared to classical, empirical therapy. Thanks to molecular diagnostics, specific aberrations can be detected, which are an indication for a correct diagnosis and prognosis and the successful use of a corresponding drug in order to target the disease.
Currently the reimbursement of personalized medicines is not coupled with that of the accompanying biomarker which often leads to a delay in reimbursement of the predictive tests as compared to the personalized medicine. To better align...